Antimicrobial peptides as promising drugs for treatment of primary viral pneumonia

The COVID-19 pandemic which began in March 2020 has again drawn attention to the problem of treating primary viral pneumonia (PVP), wherein damage to the tissues of the lower respiratory tract including functionally important alveolocytes occurs as a result of cell infection by pathogens of the Vira...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Yu. Shchelkanov, A. V. Cybulsky, V. G. Dedkov, I. V. Galkina, V. V. Maleev
Formato:	article
Lenguaje:	RU
Publicado:	Sankt-Peterburg : NIIÈM imeni Pastera 2021
Materias:	respiratory disease pneumonia primary viral pneumonia antimicrobial peptides innate immunity coronaviruses covid-19 Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/edfbbf9c547a4ae99b487a065c38211f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:edfbbf9c547a4ae99b487a065c38211f
record_format	dspace
spelling	oai:doaj.org-article:edfbbf9c547a4ae99b487a065c38211f2021-11-22T07:09:55ZAntimicrobial peptides as promising drugs for treatment of primary viral pneumonia2220-76192313-739810.15789/2220-7619-APA-1595https://doaj.org/article/edfbbf9c547a4ae99b487a065c38211f2021-11-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1595https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398The COVID-19 pandemic which began in March 2020 has again drawn attention to the problem of treating primary viral pneumonia (PVP), wherein damage to the tissues of the lower respiratory tract including functionally important alveolocytes occurs as a result of cell infection by pathogens of the Virae Kingdom. Whereas treatment of bacterial pneumonia is based on the basic approach related to the use of antibiotics (which effectiveness needs to be verified more often than ever due to the “curse of the resistance effect” — that, however, does not cancel the essence of the basic approach), efficient PVP treatment is feasible only in case of available etiotropic, but catastrophically few, drugs. Such drugs in case of the influenza A virus (Articulavirales: Orthomyxoviridae, Alphainfluenzavirus) have been known since the second part of the XXth century. However, no consensus was achieved among clinicians regarding particularly dangerous human coronaviruses (Nidovirales: Coronaviridae, Betacoronavirus) which threat has driven the world epidemiology in the XXIst century: SARS-CoV (subgenus Sarbecovirus), MERS-CoV (Merbecovirus), SARS-CoV-2 (Sarbecovirus). And we should be prepared to the fact that increase in population density and scaling up of anthropogenic impact on ecosystems elevates a probability of overcoming interspecies barriers by natural focal viruses and their penetration into the human population with adverse epidemic consequences. Therefore, PVP therapy should be developed systematically in the nearest future. Antimicrobial peptides (AMP) as the components of non-specific innate immunity against a wide range of infectious pathogens: bacteria (Bacteria), microscopic fungi (Fungi) and viruses (Virae) may serve as a platform for developing such system. Our review justifies a way to select such platform and provides well-known examples of successfully used AMP in treatment of PVP and related pathological conditions.M. Yu. ShchelkanovA. V. CybulskyV. G. DedkovI. V. GalkinaV. V. MaleevSankt-Peterburg : NIIÈM imeni Pasteraarticlerespiratory diseasepneumoniaprimary viral pneumoniaantimicrobial peptidesinnate immunitycoronavirusescovid-19Infectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 11, Iss 5, Pp 837-852 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	respiratory disease pneumonia primary viral pneumonia antimicrobial peptides innate immunity coronaviruses covid-19 Infectious and parasitic diseases RC109-216
spellingShingle	respiratory disease pneumonia primary viral pneumonia antimicrobial peptides innate immunity coronaviruses covid-19 Infectious and parasitic diseases RC109-216 M. Yu. Shchelkanov A. V. Cybulsky V. G. Dedkov I. V. Galkina V. V. Maleev Antimicrobial peptides as promising drugs for treatment of primary viral pneumonia
description	The COVID-19 pandemic which began in March 2020 has again drawn attention to the problem of treating primary viral pneumonia (PVP), wherein damage to the tissues of the lower respiratory tract including functionally important alveolocytes occurs as a result of cell infection by pathogens of the Virae Kingdom. Whereas treatment of bacterial pneumonia is based on the basic approach related to the use of antibiotics (which effectiveness needs to be verified more often than ever due to the “curse of the resistance effect” — that, however, does not cancel the essence of the basic approach), efficient PVP treatment is feasible only in case of available etiotropic, but catastrophically few, drugs. Such drugs in case of the influenza A virus (Articulavirales: Orthomyxoviridae, Alphainfluenzavirus) have been known since the second part of the XXth century. However, no consensus was achieved among clinicians regarding particularly dangerous human coronaviruses (Nidovirales: Coronaviridae, Betacoronavirus) which threat has driven the world epidemiology in the XXIst century: SARS-CoV (subgenus Sarbecovirus), MERS-CoV (Merbecovirus), SARS-CoV-2 (Sarbecovirus). And we should be prepared to the fact that increase in population density and scaling up of anthropogenic impact on ecosystems elevates a probability of overcoming interspecies barriers by natural focal viruses and their penetration into the human population with adverse epidemic consequences. Therefore, PVP therapy should be developed systematically in the nearest future. Antimicrobial peptides (AMP) as the components of non-specific innate immunity against a wide range of infectious pathogens: bacteria (Bacteria), microscopic fungi (Fungi) and viruses (Virae) may serve as a platform for developing such system. Our review justifies a way to select such platform and provides well-known examples of successfully used AMP in treatment of PVP and related pathological conditions.
format	article
author	M. Yu. Shchelkanov A. V. Cybulsky V. G. Dedkov I. V. Galkina V. V. Maleev
author_facet	M. Yu. Shchelkanov A. V. Cybulsky V. G. Dedkov I. V. Galkina V. V. Maleev
author_sort	M. Yu. Shchelkanov
title	Antimicrobial peptides as promising drugs for treatment of primary viral pneumonia
title_short	Antimicrobial peptides as promising drugs for treatment of primary viral pneumonia
title_full	Antimicrobial peptides as promising drugs for treatment of primary viral pneumonia
title_fullStr	Antimicrobial peptides as promising drugs for treatment of primary viral pneumonia
title_full_unstemmed	Antimicrobial peptides as promising drugs for treatment of primary viral pneumonia
title_sort	antimicrobial peptides as promising drugs for treatment of primary viral pneumonia
publisher	Sankt-Peterburg : NIIÈM imeni Pastera
publishDate	2021
url	https://doaj.org/article/edfbbf9c547a4ae99b487a065c38211f
work_keys_str_mv	AT myushchelkanov antimicrobialpeptidesaspromisingdrugsfortreatmentofprimaryviralpneumonia AT avcybulsky antimicrobialpeptidesaspromisingdrugsfortreatmentofprimaryviralpneumonia AT vgdedkov antimicrobialpeptidesaspromisingdrugsfortreatmentofprimaryviralpneumonia AT ivgalkina antimicrobialpeptidesaspromisingdrugsfortreatmentofprimaryviralpneumonia AT vvmaleev antimicrobialpeptidesaspromisingdrugsfortreatmentofprimaryviralpneumonia
_version_	1718417889987395584

Antimicrobial peptides as promising drugs for treatment of primary viral pneumonia

Ejemplares similares